Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter, phase 1b study, which is designed to explore the safety, efficacy and PK of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) marketed in China, in combination with APG-2575 in treating R/R Ph+ALL children, and to preliminarily establish the recommended dose of olverembatinib and APG-2575 for children based on the above results.


Clinical Trial Description

Eligible patients will receive a 6-week core treatment after screening, including a 2-week olverembatinib monotherapy and a 4-week combination therapy with olverembatinib, APG-2575 and dexamethasone, and based on the remission of leukemia after 2, 4, and 6 weeks of treatment, these patients will either continue olverembatinib alone/in combination with APG-2575 and dexamethasone as maintenance therapy or switch to other anti-tumor therapy. Toxicities of this study will be graded according to NCI CTCAT (Version 5.0). The investigator will interrupt, reduce or discontinue the dose of the investigational drug according to the correlation and grade of toxicities. The study drug can be resumed when the drug related toxicities resolve to grade 1 or below. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05495035
Study type Interventional
Source Institute of Hematology & Blood Diseases Hospital
Contact Jingliao Zhang, MD
Phone +86 22 23909196
Email zhangjingliao@ihcams.ac.cn
Status Recruiting
Phase Phase 1
Start date September 1, 2022
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05043571 - CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia Phase 1
Active, not recruiting NCT04874480 - Tegavivint for the Treatment of Relapsed or Refractory Leukemia Phase 1
Recruiting NCT05519384 - Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia Early Phase 1
Completed NCT04597086 - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients N/A
Withdrawn NCT05321940 - Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias Phase 1
Recruiting NCT04722952 - PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Phase 3
Recruiting NCT04684472 - Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies Phase 1
Recruiting NCT04470947 - Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
Recruiting NCT04282811 - Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Recruiting NCT05046444 - Solving Riddles Through Sequencing
Recruiting NCT05576532 - Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia Phase 2
Recruiting NCT05164042 - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Completed NCT02512926 - Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Phase 1
Recruiting NCT05870995 - Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia Phase 2
Recruiting NCT03799224 - Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Phase 2/Phase 3
Recruiting NCT06006403 - Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm Phase 1/Phase 2
Completed NCT00880269 - Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) Phase 2
Recruiting NCT05305859 - Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML Phase 2